Skip to main content

Table 3 Comparison of the performance of PPS with other previous signatures

From: Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients

  NSCLC Adenocarcinoma Squamous Pubmed ID Study subjects
1 year 3 year 5 year 1 year 3 year 5 year 1 year 3 year 5 year
PPS 0.784 0.808 0.764 0.802 0.806 0.727 0.757 0.812 0.788 NULL Stage 3 & 4 NSCLC
Jia Li, et al 0.596 0.539 0.415   NULL    NULL   32,020,214 NSCLC
Jie Yao, et al 0.629 0.633 0.564   NULL    NULL   33,403,045 NSCLC
Han Wang, et al   NULL   0.614 0.489 0.445   NULL   32,989,393 LUAD
Jie Zhu, et al     0.587 0.594 0.691   NULL   32,695,805 LUAD
Deng gang Fu, et al   NULL    NULL   0.596 0.694 0.631 33,005,178 LUSC
Jili Hou, et al NULL     NULL   0.593 0.537 0.593 33,466,167 LUSC